DVA vs. RGC: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at DVA and RGC, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | DVA | RGC |
|---|---|---|
| Company Name | DaVita Inc. | Regencell Bioscience Holdings Limited |
| Country | United States | Hong Kong |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Providers & Services | Pharmaceuticals |
| Market Capitalization | 8.48 billion USD | 6.84 billion USD |
| Exchange | NYSE | NasdaqCM |
| Listing Date | October 31, 1995 | July 16, 2021 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of DVA and RGC by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | DVA | RGC |
|---|---|---|
| 5-Day Price Return | 0.17% | -3.98% |
| 13-Week Price Return | -6.88% | -6.80% |
| 26-Week Price Return | -16.53% | 227.96% |
| 52-Week Price Return | -20.08% | 7,133.33% |
| Month-to-Date Return | 0.97% | -21.80% |
| Year-to-Date Return | -19.65% | 9,915.39% |
| 10-Day Avg. Volume | 1.26M | 0.12M |
| 3-Month Avg. Volume | 0.82M | 0.64M |
| 3-Month Volatility | 25.55% | 88.66% |
| Beta | 0.99 | 2.34 |
Profitability
Return on Equity (TTM)
DVA
181.22%
Health Care Providers & Services Industry
- Max
- 24.86%
- Q3
- 15.79%
- Median
- 8.56%
- Q1
- 5.75%
- Min
- -1.64%
DVA’s Return on Equity of 181.22% is exceptionally high, placing it well beyond the typical range for the Health Care Providers & Services industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
RGC
-54.75%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.85%
- Q1
- 5.40%
- Min
- -10.91%
RGC has a negative Return on Equity of -54.75%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
DVA
5.80%
Health Care Providers & Services Industry
- Max
- 11.56%
- Q3
- 5.45%
- Median
- 2.83%
- Q1
- 1.13%
- Min
- -1.71%
A Net Profit Margin of 5.80% places DVA in the upper quartile for the Health Care Providers & Services industry, signifying strong profitability and more effective cost management than most of its peers.
RGC
--
Pharmaceuticals Industry
- Max
- 40.67%
- Q3
- 19.07%
- Median
- 12.31%
- Q1
- 4.50%
- Min
- -9.91%
Net Profit Margin data for RGC is currently unavailable.
Operating Profit Margin (TTM)
DVA
15.34%
Health Care Providers & Services Industry
- Max
- 19.08%
- Q3
- 9.66%
- Median
- 4.77%
- Q1
- 2.46%
- Min
- -0.83%
An Operating Profit Margin of 15.34% places DVA in the upper quartile for the Health Care Providers & Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
RGC
--
Pharmaceuticals Industry
- Max
- 45.78%
- Q3
- 23.14%
- Median
- 16.68%
- Q1
- 7.98%
- Min
- -7.13%
Operating Profit Margin data for RGC is currently unavailable.
Profitability at a Glance
| Symbol | DVA | RGC |
|---|---|---|
| Return on Equity (TTM) | 181.22% | -54.75% |
| Return on Assets (TTM) | 4.45% | -51.38% |
| Net Profit Margin (TTM) | 5.80% | -- |
| Operating Profit Margin (TTM) | 15.34% | -- |
| Gross Profit Margin (TTM) | 31.98% | -- |
Financial Strength
Current Ratio (MRQ)
DVA
1.36
Health Care Providers & Services Industry
- Max
- 2.00
- Q3
- 1.51
- Median
- 1.29
- Q1
- 0.92
- Min
- 0.14
DVA’s Current Ratio of 1.36 aligns with the median group of the Health Care Providers & Services industry, indicating that its short-term liquidity is in line with its sector peers.
RGC
42.68
Pharmaceuticals Industry
- Max
- 4.65
- Q3
- 2.64
- Median
- 1.85
- Q1
- 1.26
- Min
- 0.78
RGC’s Current Ratio of 42.68 is exceptionally high, placing it well outside the typical range for the Pharmaceuticals industry. This indicates a very strong liquidity position, though such a high ratio may also suggest that the company is not using its assets efficiently to generate profits.
Debt-to-Equity Ratio (MRQ)
DVA
77.99
Health Care Providers & Services Industry
- Max
- 2.29
- Q3
- 1.24
- Median
- 0.74
- Q1
- 0.50
- Min
- 0.00
With a Debt-to-Equity Ratio of 77.99, DVA operates with exceptionally high leverage compared to the Health Care Providers & Services industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
RGC
0.00
Pharmaceuticals Industry
- Max
- 1.75
- Q3
- 0.82
- Median
- 0.35
- Q1
- 0.13
- Min
- 0.00
Falling into the lower quartile for the Pharmaceuticals industry, RGC’s Debt-to-Equity Ratio of 0.00 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
Interest Coverage Ratio (TTM)
DVA
4.44
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.50
- Median
- 4.52
- Q1
- 2.12
- Min
- -4.44
DVA’s Interest Coverage Ratio of 4.44 is positioned comfortably within the norm for the Health Care Providers & Services industry, indicating a standard and healthy capacity to cover its interest payments.
RGC
--
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 43.60
- Median
- 9.83
- Q1
- 2.37
- Min
- -42.71
Interest Coverage Ratio data for RGC is currently unavailable.
Financial Strength at a Glance
| Symbol | DVA | RGC |
|---|---|---|
| Current Ratio (MRQ) | 1.36 | 42.68 |
| Quick Ratio (MRQ) | 1.26 | 41.89 |
| Debt-to-Equity Ratio (MRQ) | 77.99 | 0.00 |
| Interest Coverage Ratio (TTM) | 4.44 | -- |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
DVA
0.00%
Health Care Providers & Services Industry
- Max
- 5.93%
- Q3
- 2.59%
- Median
- 1.35%
- Q1
- 0.00%
- Min
- 0.00%
DVA currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
RGC
0.00%
Pharmaceuticals Industry
- Max
- 7.14%
- Q3
- 3.45%
- Median
- 2.17%
- Q1
- 0.33%
- Min
- 0.00%
RGC currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
DVA
0.00%
Health Care Providers & Services Industry
- Max
- 185.33%
- Q3
- 74.82%
- Median
- 36.00%
- Q1
- 0.00%
- Min
- 0.00%
DVA has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
RGC
0.00%
Pharmaceuticals Industry
- Max
- 199.58%
- Q3
- 97.17%
- Median
- 53.47%
- Q1
- 22.97%
- Min
- 0.00%
RGC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | DVA | RGC |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
DVA
10.89
Health Care Providers & Services Industry
- Max
- 40.02
- Q3
- 29.75
- Median
- 21.09
- Q1
- 14.18
- Min
- 7.05
In the lower quartile for the Health Care Providers & Services industry, DVA’s P/E Ratio of 10.89 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
RGC
--
Pharmaceuticals Industry
- Max
- 45.19
- Q3
- 27.91
- Median
- 20.59
- Q1
- 15.08
- Min
- 3.79
P/E Ratio data for RGC is currently unavailable.
Price-to-Sales Ratio (TTM)
DVA
0.63
Health Care Providers & Services Industry
- Max
- 3.15
- Q3
- 1.87
- Median
- 0.74
- Q1
- 0.27
- Min
- 0.09
DVA’s P/S Ratio of 0.63 aligns with the market consensus for the Health Care Providers & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
RGC
--
Pharmaceuticals Industry
- Max
- 8.87
- Q3
- 4.56
- Median
- 2.14
- Q1
- 1.58
- Min
- 0.11
P/S Ratio data for RGC is currently unavailable.
Price-to-Book Ratio (MRQ)
DVA
101.25
Health Care Providers & Services Industry
- Max
- 7.33
- Q3
- 4.45
- Median
- 2.52
- Q1
- 1.15
- Min
- 0.66
At 101.25, DVA’s P/B Ratio is at an extreme premium to the Health Care Providers & Services industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
RGC
9.57
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.99
- Median
- 2.48
- Q1
- 1.53
- Min
- 0.59
RGC’s P/B Ratio of 9.57 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
Valuation at a Glance
| Symbol | DVA | RGC |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 10.89 | -- |
| Price-to-Sales Ratio (TTM) | 0.63 | -- |
| Price-to-Book Ratio (MRQ) | 101.25 | 9.57 |
| Price-to-Free Cash Flow Ratio (TTM) | 6.50 | -- |